---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002721"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:25:12.292178+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Olema nominates OP-3136, KAT6 inhibitor for breast cancer; IND submission targeted by end of 2024

## Summary
- OP-3136 is an orally bioavailable, potent KAT6A/B-selective inhibitor for ER+ breast cancer.
- Preclinical data show dose-dependent tumor regression alone and synergy with CDK4/6 or palazestrant.
- IND-enabling studies initiated; goal to file IND with FDA by end of 2024.
- Aurigene receives $5M milestone payment upon initiation of IND-enabling studies.

## SEC filing metadata
- accession: 0000950170-24-002721
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000095017024002721/0000950170-24-002721-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000095017024002721/olma-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002721
- JSON: https://secwatch.observer/filing/0000950170-24-002721.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002721.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.